Color Vision Tied to Bladder Survival

Patients with impaired color perception may be less likely to recognize blood in urine, potentially delaying diagnosis of cancers that rely on visible bleeding as an early warning sign.

By
Kerri Miller
March 10, 2026
5 min

Conexiant

Overview

Revise to specify the source of the 52% mortality risk and ensure it is accurately represented.

Background

Color vision deficiency is a common inherited disorder, affecting a significant portion of the male population. Its potential impact on cancer detection and survival outcomes is critical, particularly for cancers like bladder cancer where visible symptoms may be misinterpreted. Understanding the implications of CVD in cancer patients can inform screening and diagnostic strategies.

Data Highlights

Verify and update the table to ensure it accurately reflects the study's findings.

Key Findings

Patients with bladder cancer and CVD had a 52% higher 20-year mortality risk.
Overall survival was lower in bladder cancer patients with CVD compared to those without.
No significant survival difference was observed in colorectal cancer patients based on color vision status.
Color vision deficiency may lead to delayed recognition of symptoms like blood in urine, impacting timely diagnosis.
Screening practices may mitigate the effects of CVD on cancer detection.

Clinical Implications

Healthcare providers should be aware of the potential for color vision deficiency to affect cancer detection and patient outcomes, particularly in bladder cancer. Enhanced screening and patient education may be necessary to address these challenges.

Conclusion

The findings suggest a significant association between color vision deficiency and survival outcomes in bladder cancer, warranting further investigation into screening and diagnostic practices for affected patients.